Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mesoblast Ltd Ads (MESO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 456,729
  • Shares Outstanding, K 94,171
  • Annual Sales, $ 17,340 K
  • Annual Income, $ -35,290 K
  • 60-Month Beta 1.72
  • Price/Sales 26.39
  • Price/Cash Flow N/A
  • Price/Book 0.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.25
  • Low Estimate -0.25
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -13.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.17 +16.31%
on 03/12/19
5.53 -12.24%
on 03/19/19
+0.41 (+9.23%)
since 02/22/19
3-Month
3.35 +44.78%
on 12/24/18
5.53 -12.24%
on 03/19/19
+1.34 (+38.18%)
since 12/21/18
52-Week
3.35 +44.78%
on 12/24/18
8.78 -44.76%
on 10/01/18
-1.21 (-19.97%)
since 03/22/18

Most Recent Stories

More News
U.S. Healthcare Leader Joseph R. Swedish Appointed Mesoblast Chairman

Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced it has appointed Joseph R. Swedish as non-executive Chairman. Mr Swedish will succeed outgoing Chairman Brian Jamieson, who is retiring from the...

MESO : 4.85 (-0.21%)
Mesoblast Features at Upcoming U.S. Investor Conferences

Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced it will be featured at two investor conferences in March:

MESO : 4.85 (-0.21%)
Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported its financial results and operational highlights for the six months ended December 31, 2018. Pro-forma cash on hand at December 31, 2018 was US$92.0...

MESO : 4.85 (-0.21%)
Final Patient Dosed in Mesoblast Phase 3 Trial of Revascor Cell Therapy for Advanced Heart Failure

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a world leader in development and commercialization of cellular medicines, announced today that the last patient has now been dosed in the Phase 3 events-driven...

MESO : 4.85 (-0.21%)
Mesoblast Financial Results Webcast for Half Year, Q2 Ended December 31, 2018

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial results for the half year and second quarter ended December 31, 2018 in a webcast beginning at 4:30pm on Wednesday, February 20, 2019 EST;...

MESO : 4.85 (-0.21%)
New Research Coverage Highlights Symantec, YY, Workiva, Exponent, Ferroglobe, and Mesoblast -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Symantec Corporation (NASDAQ:SYMC),...

YY : 79.64 (-4.75%)
GSM : 2.12 (-4.07%)
MESO : 4.85 (-0.21%)
EXPO : 56.85 (-1.54%)
WK : 47.13 (-4.79%)
SYMC : 22.86 (-3.09%)
Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco

Mesoblast Limited (ASX:MSB; Nasdaq:MESO), world leader in the development and commercialization of cellular medicines, today reported on commercial and development plans for its lead cellular therapies...

MESO : 4.85 (-0.21%)
Phase 3 Trial of Mesoblast's Cell Therapy in Chronic Heart Failure Completes Recruitment

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), world leader in development and commercialization of allogeneic (off-the-shelf) cellular medicines, today announced that it has completed patient recruitment in...

MESO : 4.85 (-0.21%)
Mesoblast to Present at 2019 Biotech Showcase in San Francisco

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) will report on its Phase 3 trials and commercial plans at the upcoming Biotech Showcase 2019 to be held in San Francisco, CA from January 7-9, 2019.

MESO : 4.85 (-0.21%)
Meetings Held With FDA Support Mesoblast's Planned Regulatory Filing for Commercialization of Remestemcel-L in Acute GVHD

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that recent meetings held with the United States Food and Drug Administration (FDA) support its planned regulatory filing for commercialization...

MESO : 4.85 (-0.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More Share

Trade MESO with:

Business Summary

Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's...

See More

Key Turning Points

2nd Resistance Point 5.01
1st Resistance Point 4.93
Last Price 4.85
1st Support Level 4.79
2nd Support Level 4.72

See More

52-Week High 8.78
Fibonacci 61.8% 6.71
Fibonacci 50% 6.06
Fibonacci 38.2% 5.42
Last Price 4.85
52-Week Low 3.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar